Recently, DPM Company (including Beijing Digital Precision Medical Technology Co., Ltd. and Zhuhai Dipu Medical Technology Co., Ltd.) announced the successful completion of a Series C financing of over 200 million yuan. This round of financing is led by Daohe Zhiyi, followed by Huiding Investment and Yunqi Investment, with Huaxing Capital serving as the exclusive financial advisor.
Prior to this, DPM also successfully introduced multiple well-known investment institutions such as SoftBank China, Zhongguancun Longmen Investment, and Gree Financial Investment, and reached deep strategic cooperation with Johnson&Johnson China to jointly promote the company's further development in the integrated precision diagnosis and treatment market. The new round of financing not only injects sufficient capital and resources into the company, allowing DPM to further enhance product innovation, expand market influence, and achieve faster development in the field of molecular imaging and fluorescence endoscopy, but also fully reflects the high recognition of the company's development potential in the market.
Company Profile
As an enterprise incubated by the Key Laboratory of Molecular Imaging of the Chinese Academy of Sciences, DPM has successfully realized the transformation of scientific and technological achievements through the way of intellectual property rights pricing and shareholding. Relying on the laboratory's strong cutting-edge technology reserves, DPM has independently developed and produced a series of fluorescent molecular imaging products, including fluorescent endoscope camera system, fluorescent molecular imager and near-infrared fluorescent imaging system, And we have developed and planned a full range of molecular imaging equipment, including molecular imaging contrast agents and magnetic nanoparticle imaging examination equipment, becoming a leader in the field of molecular imaging technology.
With the continuous introduction of favorable policies and product iteration and upgrading, domestic high-end endoscope manufacturers have entered a golden development period of breaking foreign monopolies. DPM has created the most comprehensive product matrix for endoscopic camera systems in the industry, including the world's first registered and launched optical 8CMOS 3D4K fluorescence endoscopic camera system in December 2022, the world's first registered and launched 8K fluorescence endoscopic camera system in September 2023, as well as the 4K fluorescence endoscopic camera system and white light endoscopic camera system product matrix. More than 20 products have been registered and launched, and they have also obtained two EU CE certifications.
With the strong accumulation of molecular imaging technology from the Chinese Academy of Sciences, DPM Company has already taken the lead in the field of fluorescent endoscope products! On the basis of the nano special research and development of the Ministry of Science and Technology in the early stage, the company will further deepen the research and production of molecular targeted probes for fluorescence endoscopes in the future, further improve the specificity of tumor diagnosis in clinical practice, and provide reliable tools and methods for early and accurate diagnosis and treatment of tumor patients. With the support of the National Natural Science Foundation of China's major research instrument project, the team has taken the lead in developing primate research equipment based on nonlinear response of magnetic nanoparticles internationally. The detection sensitivity of this equipment is more than a thousand times that of traditional magnetic resonance products, which will provide more accurate disease live diagnosis tools for precision medicine in the future. In the future, the DPM team will accelerate product conversion speed and continuously provide stronger tools and products for the field of big health and precision screening!
Company Honors
The products independently developed by DPM Company have undergone strict evidence-based medicine efficacy clinical trials, proving their clinical efficacy and safety, and have obtained special approval from the National Medical Products Administration and the Beijing Municipal Medical Products Administration for innovative medical devices. In 2021, DPM Company took the lead in formulating relevant technical standards in the industry and for the first time in China, released two group standards in the field of fluorescence endoscopes: "Near infrared fluorescence camera system for medical endoscope functional supply devices" and "Cold light source containing near-infrared excitation for medical endoscope functional supply devices". In 2023, the team led a joint effort with 14 units including the Medical Device Evaluation Center of the National Medical Products Administration, the China Food and Drug Control Research Institute, the Guangdong Medical Device Quality Supervision and Testing Institute, Peking University People's Hospital, and Beijing Union Medical College Hospital to draft the "Image Quality Evaluation Specification for Endoscopic Fluorescent Camera Systems".
The products independently developed by DPM Company have undergone strict evidence-based medicine efficacy clinical trials, proving their clinical efficacy and safety, and have obtained special approval from the National Medical Products Administration and the Beijing Municipal Medical Products Administration for innovative medical devices. In 2021, DPM Company took the lead in formulating relevant technical standards in the industry and for the first time in China, released two group standards in the field of fluorescence endoscopes: "Near infrared fluorescence camera system for medical endoscope functional supply devices" and "Cold light source containing near-infrared excitation for medical endoscope functional supply devices". In 2023, the team led a joint effort with 14 units including the Medical Device Evaluation Center of the National Medical Products Administration, the China Food and Drug Control Research Institute, the Guangdong Medical Device Quality Supervision and Testing Institute, Peking University People's Hospital, and Beijing Union Medical College Hospital to draft the "Image Quality Evaluation Specification for Endoscopic Fluorescent Camera Systems". DPM Company is the crystallization of research and accumulation in multiple major national projects. The preliminary research has received support from national key projects such as the National 973 Program, the National Natural Science Foundation of China's Major Scientific Research Instrument Project, and the Ministry of Science and Technology's Nanotechnology Project. In addition, DPM company has also led the key project of "Digital Diagnosis and Treatment Equipment Research and Development" of the Ministry of Science and Technology of China, and has made significant breakthroughs in precise imaging during liver cancer surgery. Leading the list of "Intelligent Assisted Therapy Products" in the "Artificial Intelligence Medical Device Innovation Task" by the Ministry of Industry and Information Technology of China. Led by the National Development and Reform Commission's special support for the integration and application of biotechnology and information technology. In terms of core technology, DPM Company has obtained over a hundred intellectual property rights, including US invention patents, PCT invention patents, national invention patents, and software copyrights. The related achievements have also won honors such as the Second Prize of National Science and Technology Progress Award, the Second Prize of National Technology Invention Award, the First Prize of Huang Jiasi's Science and Technology Progress Award of the Chinese Society of Biomedical Engineering, the Gold Award of the 43rd Geneva International Invention Exhibition, the Gold Award of the 23rd National Invention Exhibition, and the First Prize of the China Medical Device Innovation and Entrepreneurship Competition. In addition, DPM Company has been selected by the National Health Commission as one of the eighth batch of excellent domestic endoscopic product enterprises, and has won the second prize in the HCOOL 2022 Global Entrepreneurship Competition. It has entered the top 100 most innovative medical device products (solutions) in 2023, as well as one of the Top 100 Future Medical Products and Top 10 Most Concerned Enterprises in 2023.
Dr. Chi Chongwei, CEO of DPM Company, stated:
Precision medicine, as an important way to improve the level of diagnosis and treatment and achieve personalized healthcare, is increasingly receiving attention. Molecular imaging technology is considered one of the top ten cutting-edge medical science fields with the greatest potential for future development, and its rise has brought new opportunities for the development of precision medicine. At present, DPM company has established a business model of "equipment+consumables" in the field of precision surgery through technologies such as optical molecular imaging fluorescence endoscopy, and combined with molecular imaging contrast agents. In this round of financing, well-known investment institutions such as Daohe Zhiyi, Huiding Investment, and Yunqi Investment have recognized the unique development potential and industry position of DPM Company. They believe that DPM Company will achieve rapid development in the future market and work together with partners to create brilliance.
Mr. Zhou Hao, Managing Partner of Daohezhi Medical, stated:
As a platform under Daohe Long Term Investment that focuses on medical and health investment, Daohe Zhiyi has always adhered to the concept of long-term investment and is committed to exploring and cultivating potential long-term assets in the medical industry. DPM is a leading enterprise in the Chinese molecular imaging industry, and fluorescence endoscopy is a projection of the company's molecular imaging technology platform in surgical surgery. It is expected to achieve breakthroughs in new fields of molecular imaging such as magnetic nanomaterials and contrast agents in the future. We will continue to support and accompany the company's development, and jointly promote the progress of China's molecular imaging industry.
Dr. He Xin, Managing Partner of Huiding Investment, stated:
I am very pleased to have the opportunity to support the development of DPM. Against the backdrop of China's strong support for technological innovation and import substitution of medical devices, DPM has transformed into domestic independent innovation, the world's first optical 3D fluorescence endoscopy system, and has obtained cooperation from international device giants. Huiding looks forward to helping DPM bring greater clinical value and benefit more patients.
The person in charge of Yunqi Medical Investment stated:
The precision and intelligence of minimally invasive surgery are the trend, and molecular imaging is a revolutionary technology in precision surgery. DPM Company leads the industry in mastering multiple underlying core technologies in the fields of molecular imaging and artificial intelligence. Its rich product matrix, excellent product performance, and innovative technological strength have been widely recognized clinically, achieving true domestic substitution of high-end medical devices in this field, Looking forward to the near future, the company will compete with foreign leaders in the international market with its own original Chinese technology.
Mr. Xie Yijing, Managing Director of Huaxing Capital and Head of Medical and Life Technology Business Unit, stated:
Molecular imaging is a revolutionary tool in the era of precision medicine. DPM relies on the top research engine of the Chinese Academy of Sciences and is guided by clinical value for industrial transformation. Driven by clinical benefits, the company has built a core team from medical research and development to manufacturers. It has successfully developed and commercialized a comprehensive product portfolio based on molecular imaging, with huge imagination space. Huaxing Capital is honored to assist DPM in completing this round of financing and to help the company become a leader in the era of precision medicine in China, benefiting patients.
Future prospects
Looking ahead to the future, DPM company will rely on molecular imaging technology to further expand from precision surgery to precision health. The company is full of confidence in its future development, and will never forget its original intention and forge ahead!
